NSEDCP
HAE icon

NJ State Employees Deferred Compensation Plan’s Haemonetics HAE Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,000
Closed -$361K – 543
2019
Q2 		$361K Sell
3,000
-3,000
-50% -$295K 0.06% 366
2019
Q1 		$525K Buy
+6,000
New +$546K 0.1% 253

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's HAE Position: Q3 2019 in Review

NJ State Employees Deferred Compensation Plan sold out of Haemonetics (HAE) in Q3 2019, closing a stake of 3,000 shares — an estimated $361K sold.

NJ State Employees Deferred Compensation Plan first reported a position in HAE in Q1 2019 and held it in 2 quarters. The position peaked at $525K in Q1 2019. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

  • NJ State Employees Deferred Compensation Plan reported no remaining Haemonetics position as of Q3 2019 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 3,000 Haemonetics shares in Q3 2019, an estimated $361K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Haemonetics in Q1 2019 and held it in 2 quarters.
  • NJ State Employees Deferred Compensation Plan's Haemonetics position peaked at $525K in Q1 2019.
  • 275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2019, filed 18 Oct 2019.